IART
HealthcareIntegra LifeSciences Holdings Corporation · Medical - Devices · $1B
What is Integra LifeSciences Holdings Corporation?
Integra LifeSciences Holdings Corporation is a small-cap medical device company focused on neurosurgery, extremity reconstruction, and wound care. Headquartered in Princeton, NJ, it serves hospitals, surgery centers, and healthcare providers across the US and internationally.
Integra operates through two segments: Codman Specialty Surgical and Tissue Technologies. The Codman segment covers neurosurgery and neuro critical care products, including dural repair, cerebrospinal fluid management, and cranial stabilization. The Tissue Technologies segment focuses on regenerative products for wound care, hernia repair, nerve repair, and tendon repair. Products reach customers through direct sales forces and distribution channels, serving hospitals, integrated health networks, and group purchasing organizations worldwide.
Integra LifeSciences was founded in 1995 and is headquartered in Princeton, New Jersey.
- Neurosurgery and neuro critical care instruments
- Dural repair and cranial stabilization products
- Cerebrospinal fluid management devices
- Regenerative wound care and tissue repair products
- Surgical instrumentation and lighting systems
Is IART a Good Stock to Buy?
UQS Score rates IART as Below Average overall.
Among the five pillars, Valuation stands out as Attractive — meaning the stock may be priced at a discount relative to its fundamentals, which could interest value-oriented investors. Risk registers as Neutral, suggesting the company's financial risk profile is neither particularly alarming nor reassuring relative to sector peers.
Quality, Moat, and Growth all score as Weak — pointing to challenges in profitability consistency, competitive differentiation, and near-term expansion prospects that weigh on the overall rating.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does IART pay dividends?
No — Integra LifeSciences Holdings Corporation does not currently pay a dividend.
Integra LifeSciences does not currently pay a dividend. For a medical device company navigating operational challenges and investing in product development across two business segments, retaining capital rather than distributing it is a common strategic choice. Income-focused investors should factor this into their assessment of IART.
When does IART report earnings?
Integra LifeSciences reports earnings on a quarterly cadence, typical for US-listed equities.
The company's recent results reflect the pressures visible in its UQS pillar profile — particularly in Quality and Growth, where performance has lagged sector peers. Execution across both the Codman Specialty Surgical and Tissue Technologies segments remains a key area to watch.
For the most recent quarter's results and guidance, visit Integra LifeSciences' official investor relations page.
IART Price History
-84.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Integra LifeSciences Holdings Corporation?
Based on Integra LifeSciences Holdings Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
IART Long-term Outlook
The fundamental outlook for IART is cautious. With Growth and Quality both rated Weak, the near-term trajectory faces headwinds from operational challenges and limited top-line momentum. However, an Attractive Valuation label suggests the market may already be pricing in much of the difficulty, leaving room for recovery if execution improves. The Neutral Risk rating indicates the balance sheet is not in acute distress, which provides some stability as the company works through its challenges.
Growth drivers
- Expansion of regenerative tissue technology into new wound care indications
- International market penetration across Asia Pacific and Europe
- Cross-selling opportunities between the Codman and Tissue Technologies segments
Key risks
- Continued weakness in Quality and Moat pillars limiting pricing power
- Execution risk across two distinct business segments
- Competitive pressure in both neurosurgery and wound care markets
IART vs Peers
Integra LifeSciences operates in a competitive medical device landscape alongside companies targeting overlapping surgical and neuro-focused markets.
InMode focuses on energy-based minimally invasive surgical platforms, giving it a distinct technology profile compared to Integra's implant and regenerative tissue approach.
CeriBell specializes in rapid EEG monitoring for neuro critical care, competing narrowly with Integra's intracranial monitoring and neuro critical care product lines.
SS Innovations targets robotic surgical systems, representing a technology-forward alternative in the broader surgical instrumentation space where Integra also competes.
Frequently Asked Questions
What does Integra LifeSciences do?
Integra LifeSciences develops and markets surgical implants and medical instruments across two segments: Codman Specialty Surgical, which covers neurosurgery and neuro critical care, and Tissue Technologies, which focuses on regenerative wound care and surgical tissue repair. Its products are sold to hospitals, surgery centers, and healthcare providers globally.
Does IART pay dividends?
No, Integra LifeSciences does not currently pay a dividend. The company retains capital to support its operations and product development across its two business segments. Investors seeking income should note the absence of a dividend when evaluating IART.
When does IART report earnings?
Integra LifeSciences reports on a quarterly cadence, consistent with US-listed healthcare companies. For confirmed dates and the latest results, check the investor relations section of the company's official website.
Is IART a good stock to buy?
UQS Score rates IART as Below Average overall. While Valuation is Attractive and Risk is Neutral, the Quality, Moat, and Growth pillars are all rated Weak. Whether that profile suits your investment approach depends on your risk tolerance and time horizon. View the full pillar breakdown on UQS Pro.
Is IART overvalued?
Based on the UQS Valuation pillar, IART is rated Attractive — suggesting the stock may be trading at a discount relative to its fundamentals. This can reflect market skepticism about near-term growth, but it also means investors may not be paying a premium for the business at current levels.
How does IART compare to its competitors?
Integra competes with companies like InMode, CeriBell, and SS Innovations across different niches of the surgical and neuro critical care market. Each competitor brings a distinct technology focus, from energy-based platforms to robotic surgery, while Integra's strength lies in its broad implant and regenerative tissue portfolio.
What is IART's market cap bracket?
IART is classified as a small-cap stock. This places it in a segment of the market that can offer higher growth potential but also carries greater volatility and liquidity risk compared to large-cap or mega-cap healthcare peers.
Who founded Integra LifeSciences?
Integra LifeSciences was founded in 1995. For detailed founding history and leadership background, the company's official website and public filings provide comprehensive information.
Is IART a long-term quality investment?
As a long-term quality indicator, IART's UQS profile raises questions — Quality, Moat, and Growth are all rated Weak, which can signal challenges in sustaining competitive advantage and earnings consistency over time. The Attractive Valuation may offer a margin of safety, but long-term conviction would require improvement across multiple pillars.
What is the main competitive advantage of Integra LifeSciences?
Integra's breadth across neurosurgery and regenerative tissue — including roughly 40,000 instrument patterns — gives it wide product coverage across hospital and surgical settings. However, the UQS Moat pillar is currently rated Weak, suggesting this breadth has not yet translated into a durable competitive edge by the model's assessment.
What sector does IART belong to?
IART operates in the Healthcare sector, specifically within medical devices and surgical instruments. It serves neurosurgery, extremity reconstruction, and wound care markets through direct sales and distribution channels in the US and internationally.
Unlock Full IART Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access detailed financial metrics and trend data
- ✓Compare IART against sector peers side by side
- ✓See the complete Quality and Moat breakdown
- ✓Track changes to IART's UQS rating over time
- ✓Get the full analyst-style view in one dashboard
Pro Analysis
IART — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 38.9 | 16.1 | 22.0 | 27.3 | 59.8 | 100.0 | +6.2 |
| May 8, 2026 | 32.7 | 4.6 | 22.0 | 27.3 | 36.9 | 100.0 | -4.8 |
| Apr 2, 2026 | 37.5 | 13.2 | 22.0 | 27.2 | 55.2 | 100.0 | — |
IART — Pillar Breakdown
Quality
— 16.1/100 (25%)Integra LifeSciences Holdings Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 27.3/100 (20%)Integra LifeSciences Holdings Corporation faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 59.8/100 (15%)Integra LifeSciences Holdings Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 100.0/100 (15%)Integra LifeSciences Holdings Corporation appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 22/100 (25%)Integra LifeSciences Holdings Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for IART.
Score Composition
Financial Data
More Stock Analysis
How is the IART UQS Score Calculated?
The UQS (Unified Quality Score) for Integra LifeSciences Holdings Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Integra LifeSciences Holdings Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Integra LifeSciences Holdings Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.